MedTrace Logo

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

NCT05282420 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2022-03-16

No results posted yet for this study

Summary

this study will compare the efficacy and safety of use either Ranibizumab and Aflibercept in treatment of macular edema resulting from non ischemic central retinal vein occlusion in patients younger than 5o years old

Conditions

  • Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Interventions

PROCEDURE

intravitreal injection of Ranibizumab

intravitreal injection of Anti-VEGF Ranibizumab (Lucentis®; manufactured in the United States by Genentech/Roche)

PROCEDURE

intravitreal injection of Aflipercept

intravitreal injection of Anti-VEGF Aflibercept (Eylea®; manufactured in the United States)

DRUG

Ranibizumab

Ranibizumab

DRUG

Aflibercept

Aflipercept

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-04-01
Completion
2022-05-31
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05282420 on ClinicalTrials.gov